Public Assessment Report UKPAR. Levonorgestrel 1.5 mg tablet. (levonorgestrel). UK Licence No: PL 41947/0006. ELC Group s.r.o.

Transcription

1 Public Assessment Report UKPAR Levonorgestrel 1.5 mg tablet (levonorgestrel). UK Licence No: PL 41947/0006 ELC Group s.r.o. 1

2 LAY SUMMARY Levonorgestrel 1.5 mg tablet (Levonorgestrel, tablet, 1.5 mg) This is a summary of the Public Assessment Report (PAR) for Levonorgestrel 1.5 mg tablet (PL 41947/0006). It explains how Levonorgestrel 1.5 mg tablet was assessed and its authorisation recommended, as well as its conditions of use. It is not intended to provide practical advice on how to use Levonorgestrel 1.5 mg tablet. For practical information about using Levonorgestrel 1.5 mg tablet patients should read the package leaflet or contact their doctor or pharmacist. What is Levonorgestrel 1.5 mg tablet and what is it used for? Levonorgestrel 1.5 mg tablet contains the active ingredient levonorgestrel, which is a synthetic derivative of the naturally occurring female sex hormone progesterone. This medicine is an oral emergency contraceptive. Emergency contraception is a rescue method intended to prevent pregnancy after unprotected intercourse or failure of contraception. This medicine is identical to Levonorgestrel 1.5 mg Tablet (PL 32821/0053) which was first granted a Marketing Authorisation on 29 August How is Levonorgestrel 1.5 mg tablet used? The pharmaceutical form of this medicine is a tablet and the route of administration is oral. The patient should take Levonorgestrel 1.5 mg tablet as soon as possible, preferably within 12 hours and no later than 72 hours (3 days) after unprotected intercourse or after failure of a contraceptive method. Levonorgestrel 1.5 mg tablet is most effective if the patient takes it as soon as possible after unprotected intercourse. Levonorgestrel 1.5 mg tablet can only prevent the patient from becoming pregnant if they take it within 72 hours after unprotected intercourse. It will not work if the patient is already pregnant. If the patient has had unprotected sex after they have taken Levonorgestrel 1.5 mg tablet, it will not stop them from becoming pregnant. The patient should always use this medicine exactly as their doctor or pharmacist has told them. The patient should check with their doctor or pharmacist if they are not sure. This medicine is intended for oral use. The tablet should be swallowed with a glass of water and should not be chewed. Please refer to section 3 of the package leaflet for information on how to use this medicine. Levonorgestrel 1.5 mg tablet can be obtained only with a prescription. For further information on how Levonorgestrel 1.5 mg tablet is used, refer to the package leaflet and Summary of Product Characteristics available on the Medicines and Healthcare products Regulatory Agency (MHRA) website. How does Levonorgestrel 1.5 mg tablet work? The precise mode of action of Levonorgestrel 1.5 mg tablet is not known. Most likely it stops the patient s ovaries from the release of an egg. Perhaps there are other processes involved, including the 2

3 prevention of implantation of a fertilised ovum into the uterus. It is not effective once the process of nidation (implantation) has begun. This tablet is intended only as emergency contraception, not as a regular contraceptive method because these are less effective than the 'normal' birth control pill ("the pill"). What benefits of Levonorgestrel 1.5 mg tablet have been shown in studies? The application for Levonorgestrel 1.5 mg tablet is considered to be identical to the previously authorised application for Levonorgestrel 1.5 mg Tablet (PL 32821/0053), with the same benefits and risks, so, no new studies have been provided for Levonorgestrel 1.5 mg tablet. However, reference is made to the studies for Levonorgestrel 1.5 mg Tablet (PL 32821/0053). The company (ELC Group s.r.o) referred to the data that Famy Care Europe Limited provided for the grant of the licence for Levonorgestrel 1.5 mg Tablet (PL 32821/0053) as a basis for the grant of an identical licence for Levonorgestrel 1.5 mg tablet (PL 41947/0006). What are the possible side effects from Levonorgestrel 1.5 mg tablet? Like all medicines, this medicine can cause side effects, although not everybody gets them. Levonorgestrel 1.5 mg tablet (PL 41947/0006) is considered to be identical to the previously authorised application for Levonorgestrel 1.5 mg Tablet (PL 32821/0053) with the same benefits and risks. For a full list of all the side effects reported with Levonorgestrel 1.5 mg tablet see section 4 of the package leaflet, available on the Medicines and Healthcare products Regulatory Agency (MHRA) website. Why is Levonorgestrel 1.5 mg tablet approved? No new or unexpected safety concerns arose from this application. The MHRA, therefore, considered that the benefits of Levonorgestrel 1.5 mg tablet outweigh their risks; and the grant of a Marketing Authorisation (licence) was recommended. What measures are being taken to ensure the safe and effective use of Levonorgestrel 1.5 mg tablet? A Risk Management Plan has been developed to ensure that Levonorgestrel 1.5 mg tablet is used as safely as possible. Based on this plan, safety information has been included in the Summary of Product Characteristics and the package leaflet for Levonorgestrel 1.5 mg tablet including the appropriate precautions to be followed by healthcare professionals and patients. Known side effects are continuously monitored. Furthermore new safety signals reported by patients/healthcare professionals will be monitored/reviewed continuously. Other information about Levonorgestrel 1.5 mg tablet A Marketing Authorisation was granted in the UK on 17 June The full PAR for Levonorgestrel 1.5 mg tablet follows this summary. For more information about treatment with Levonorgestrel 1.5 mg tablet read the package leaflet, or contact your doctor or pharmacist. This summary was last updated in July

4 TABLE OF CONTENTS I Introduction Page 5 II Quality aspects Page 6 III Non-clinical aspects Page 8 IV Clinical aspects Page 8 V User consultation Page 9 VI Overall conclusion, benefit/risk assessment and recommendation Page 9 4

5 I INTRODUCTION The Medicines and Healthcare products Regulatory Agency (MHRA) granted ELC Group s.r.o a Marketing Authorisation for the medicinal product Levonorgestrel 1.5 mg tablet (PL 41947/0006) on 17 June The product is a prescription-only medicine (POM) and is indicated as an emergency contraception within 72 hours of unprotected sexual intercourse or failure of a contraceptive method. This application was submitted as an abridged application according to Article 10c of Directive 2001/83/EC, as amended. The application cross-refers to Levonorgestrel 1.5 mg Tablet (PL 32821/0053) which was first authorised to Famy Care Europe Limited on 29 August 2014 via the decentralised procedure with Portugal as reference member state (RMS) and Belgium, Spain and the UK as concerned member states (CMS). The primary mechanism of action of levonorgestrel is blockade and/or delay of ovulation via suppression of the luteinizing hormone (LH) peak. Levonorgestrel interferes with the ovulatory process only if it is administered before the onset of the LH surge. Levonorgestrel has no emergency contraceptive effect when administered later in the cycle. No new data were submitted nor were necessary to be submitted for this application, as the data are identical to that of the previously granted cross-referenced product. 5

6 II QUALITY ASPECTS II.1 Introduction This is an abridged application for Levonorgestrel 1.5 mg tablet (PL 41947/0006) submitted under Article 10c of Directive 2001/83/EC, as amended. The application cross-refers to Levonorgestrel 1.5 mg Tablet (PL 32821/0053) which was first authorised to Famy Care Europe Limited on 29 August The application is considered valid. II.2. Drug Substance Drug substance specification The proposed drug substance specification is consistent with the details registered for the cross-reference product. II.3. Medicinal Product Name The proposed product name for this application is Levonorgestrel 1.5 mg tablet (PL 41947/0006). The product has been named in line with current requirements. Strength, pharmaceutical form, route of administration, container and pack sizes Each tablet contains 1.5 mg of levonorgestrel. The finished product is packed into PVC/ PVDC Aluminum-blisters containing one tablet. The blister is packed in a carton. The proposed shelf life of the product is 2 years with no special storage conditions The proposed packaging, shelf-life and storage conditions are consistent with the details registered for the cross-reference product. Legal status On approval, the product will be available as a prescription-only medicine (POM). Marketing Authorisation Holder/Contact Persons/Company ELC Group s.r.o, Karolinská 650/1, Karlín Prague 8, , Czech Republic. The Qualified Person (QP) responsible for pharmacovigilance is stated and a satisfactory CV has been provided. Manufacturers The proposed manufacturing sites are consistent with those registered for the cross-reference product and evidence of Good Manufacturing Practice (GMP) compliance has been provided. Qualitative and quantitative composition The proposed composition is consistent with the details registered for the cross-reference product. Manufacturing process The proposed manufacturing processes are consistent with the details registered for the cross-reference product and the maximum batch size is stated. 6

7 Finished product/shelf-life specification The proposed finished product specification is in line with the details registered for the cross-reference product. TSE Compliance With the exception of lactose monohydrate, none of the excipients contain materials of animal or human origin. This is consistent with the cross-reference product. The applicant has provided a declaration that the milk used in the production of lactose monohydrate is sourced from healthy animals under the same conditions as that for human consumption. Confirmation has also been given that the magnesium stearate used in the tablets is of vegetable origin. Bioequivalence No bioequivalence data are required to support this simple abridged application because the proposed product is manufactured to the same formula utilising the same processes as the cross-reference product, Levonorgestrel 1.5 mg Tablet (PL 32821/0053). Expert Report The applicant cross-refers to the data for Levonorgestrel 1.5 mg Tablet (PL 32821/0053) to which this application is claimed to be identical. This is acceptable. Product Name and Appearance See Section II.3 Medicinal Product; Name for details of the proposed product name. The appearance of each product is identical to that of the cross-reference product. II.4 Discussion on chemical, pharmaceutical and biological aspects The data submitted with the application is acceptable. The grant of a Marketing Authorisation is recommended. 7

8 III NON-CLINICAL ASPECTS Introduction As this is an abridged application submitted under Article 10c of Directive 2001/83/EC, as amended, no new non-clinical data have been supplied and none are required. Ecotoxicity/environmental risk assessment (ERA) Suitable justification has been provided for non-submission of an Environmental Risk Assessment. As the application is an identical version of an already authorised product, it is not expected that environmental exposure will increase following approval of the Marketing Authorisation for the proposed product. Discussion on the non-clinical aspects The grant of a Marketing Authorisation is recommended. IV CLINICAL ASPECTS Introduction As this is an abridged application submitted under Article 10c of Directive 2001/83/EC, as amended, no new clinical data have been supplied and none are required. Risk Management Plan (RMP) The marketing authorisation holder (MAH) has submitted a risk management plan (RMP), in accordance with the requirements of Directive 2001/83/EC as amended, describing the pharmacovigilance activities and interventions designed to identify, characterise, prevent or minimise risks relating to Levonorgestrel 1.5 mg tablet. A summary of safety concerns and planned risk minimisation activities, as approved in the RMP, are listed below: Summary table of safety concerns: 8

9 Routine pharmacovigilance and routine risk minimisation are proposed for all safety concerns. Discussion on the clinical aspects The grant of a Marketing Authorisation is recommended. V User consultation User-testing of the PIL for Levonorgestrel 1.5 mg tablet has been accepted based on the bridging report provided by the applicant making reference to the successful user-testing of the PIL for Levonorgestrel 1.5 mg Tablet (PL 32821/0053) as the parent PIL. VI Overall conclusion, benefit/risk assessment and recommendation The quality of the product is acceptable, and no new non-clinical or clinical safety concerns have been identified. The applicant s product is identical to the cross-reference product. Extensive clinical experience with levonorgestrel is considered to have demonstrated the therapeutic value of the compound. The benefit/risk balance is, therefore, considered to be positive. 9

10 Summaries of Product Characteristics (SmPC), Patient Information Leaflets (PIL) and Labels The Summary of Product Characteristics and Patient Information Leaflet (PIL) are consistent with the details registered for the cross-reference products. In accordance with Directive 2010/84/EU the Summaries of Product Characteristics (SmPCs) and Patient Information Leaflets (PILs) for products granted Marketing Authorisations at a national level are available on the MHRA website. The approved labelling for Levonorgestrel 1.5 mg tablet is presented below: 10